CA
NZ
UK
AU
IND
US
…
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Baxter International is a global healthcare company supplying renal-care products, IV therapies and hospital medical devices. Long-term demand for dialysis consumables, intravenous therapies and hospital devices could support recurring revenue as populations age. Investors may find the company attractive for its diversified exposure to essential hospital consumables and devices and for scale advantages in manufacturing and distribution.
It faces risks from regulatory and product‑liability exposure including recalls, pricing and reimbursement pressure, and execution and integration challenges from acquisitions that investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -505.00M | -289.00M | 242.00M | -2353.00M | 1477.00M |
| Minority interest | 0.00M | -11.00M | -7.00M | 12.00M | 11.00M |
| Net income | -957.00M | -649.00M | 2656.00M | -2421.00M | 1284.00M |
| Selling general administrative | 2890.00M | 2967.00M | 3938.00M | 3862.00M | 2878.00M |
| Selling and marketing expenses | - | 1764.00M | 985.00M | 25.00M | -11.00M |
| Gross profit | 3379.00M | 3984.00M | 4150.00M | 5397.00M | 5105.00M |
| Reconciled depreciation | 981.00M | 997.00M | 1263.00M | 1403.00M | 890.00M |
| Ebit | -215.00M | 119.00M | 750.00M | -549.00M | 779.00M |
| Ebitda | 766.00M | 1116.00M | 1734.00M | 854.00M | 1669.00M |
| Depreciation and amortization | 981.00M | 997.00M | 984.00M | 1403.00M | 890.00M |
| Non operating income net other | - | - | - | -15.00M | -41.00M |
| Operating income | -308.00M | 14.00M | 707.00M | -549.00M | 779.00M |
| Other operating expenses | 11552.00M | 10622.00M | 9653.00M | 14244.00M | 11074.00M |
| Interest expense | 290.00M | 408.00M | 508.00M | 395.00M | 192.00M |
| Tax provision | 395.00M | 37.00M | -34.00M | 68.00M | 182.00M |
| Interest income | 52.00M | 67.00M | 70.00M | 20.00M | 192.00M |
| Net interest income | -238.00M | -341.00M | -442.00M | -395.00M | -192.00M |
| Extraordinary items | -57.00M | -312.00M | 2482.00M | - | 0.00M |
| Non recurring | - | - | - | 2812.00M | - |
| Income tax expense | 395.00M | 37.00M | 61.00M | 68.00M | 182.00M |
| Total revenue | 11244.00M | 10636.00M | 10360.00M | 15113.00M | 12784.00M |
| Total operating expenses | 3687.00M | 3970.00M | 3443.00M | 4528.00M | 3395.00M |
| Cost of revenue | 7865.00M | 6652.00M | 6210.00M | 9716.00M | 7679.00M |
| Total other income expense net | -197.00M | -303.00M | -465.00M | -1804.00M | 698.00M |
| Net income from continuing ops | -900.00M | -326.00M | -69.00M | -2421.00M | 1295.00M |
| Net income applicable to common shares | -957.00M | -649.00M | 2656.00M | -2433.00M | 1284.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 20055.00M | 25782.00M | 28276.00M | 28287.00M | 33521.00M |
| Intangible assets | 4369.00M | 5223.00M | 6079.00M | 6793.00M | 7792.00M |
| Other current assets | 740.00M | 3313.00M | 839.00M | 399.00M | 390.00M |
| Total liab | 13953.00M | 18758.00M | 19808.00M | 22392.00M | 24400.00M |
| Total stockholder equity | 6129.00M | 6964.00M | 8402.00M | 5833.00M | 9077.00M |
| Deferred long term liab | - | - | - | 119.00M | 99.00M |
| Other current liab | 1741.00M | 2363.00M | 2050.00M | 1917.00M | 2189.00M |
| Common stock | 683.00M | 683.00M | 683.00M | 683.00M | 683.00M |
| Capital stock | 683.00M | 683.00M | 683.00M | 683.00M | 683.00M |
| Retained earnings | 13705.00M | 14929.00M | 16114.00M | 14050.00M | 17065.00M |
| Other liab | - | - | - | 1959.00M | 2493.00M |
| Good will | 4929.00M | 5275.00M | 6514.00M | 6843.00M | 9836.00M |
| Other assets | 520.00M | 3064.00M | - | 653.00M | 835.00M |
| Cash | 1966.00M | 1764.00M | 3194.00M | 1718.00M | 2951.00M |
| Cash and equivalents | 1966.00M | 1764.00M | - | 1718.00M | 2951.00M |
| Total current liabilities | 2970.00M | 6511.00M | 6503.00M | 4745.00M | 4236.00M |
| Current deferred revenue | 141.00M | 131.00M | 148.00M | 164.00M | 162.00M |
| Net debt | 8037.00M | 11685.00M | 11170.00M | 15495.00M | 15359.00M |
| Short term debt | 84.00M | 2832.00M | 2796.00M | 1525.00M | 639.00M |
| Short long term debt | 3.00M | 2752.00M | 2668.00M | 1404.00M | 511.00M |
| Short long term debt total | 10003.00M | 13449.00M | 14364.00M | 17213.00M | 18310.00M |
| Other stockholder equity | -4505.00M | -4638.00M | -4841.00M | -5067.00M | -5291.00M |
| Property plant equipment | 3186.00M | 3176.00M | - | 5529.00M | 5808.00M |
| Total current assets | 6872.00M | 8853.00M | 9600.00M | 8011.00M | 8872.00M |
| Long term investments | 103.00M | 109.00M | 194.00M | 247.00M | 154.00M |
| Net tangible assets | - | - | - | -7803.00M | 3796.00M |
| Net receivables | 1932.00M | 1730.00M | 2743.00M | 2752.00M | 2713.00M |
| Long term debt | 9473.00M | 10374.00M | 11130.00M | 15232.00M | 17081.00M |
| Inventory | 2232.00M | 2046.00M | 2824.00M | 2718.00M | 2453.00M |
| Accounts payable | 999.00M | 968.00M | 1241.00M | 1139.00M | 1246.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 62.00M | 44.00M |
| Accumulated other comprehensive income | -3754.00M | -4010.00M | -3554.00M | -3833.00M | -3380.00M |
| Common stock total equity | - | - | - | 683.00M | 683.00M |
| Retained earnings total equity | - | - | - | 14050.00M | 17065.00M |
| Treasury stock | - | - | - | -11389.00M | -11488.00M |
| Non currrent assets other | 596.00M | 2942.00M | 548.00M | 584.00M | 683.00M |
| Non current assets total | 13183.00M | 16929.00M | 18676.00M | 20276.00M | 24649.00M |
| Capital lease obligations | 304.00M | 323.00M | 566.00M | 577.00M | 650.00M |
| Long term debt total | 9473.00M | 10374.00M | - | 15232.00M | 17149.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -626.00M | 3187.00M | -931.00M | -11200.00M |
| Change to liabilities | - | - | - | -349.00M | 212.00M |
| Total cashflows from investing activities | 2841.00M | -626.00M | 3213.00M | -931.00M | -11200.00M |
| Net borrowings | -3791.00M | -531.00M | -2935.00M | -899.00M | 9228.00M |
| Total cash from financing activities | -4216.00M | -1081.00M | -3489.00M | -1438.00M | 8245.00M |
| Change to operating activities | - | - | - | -440.00M | -58.00M |
| Net income | -957.00M | -326.00M | 181.00M | -2421.00M | 1295.00M |
| Change in cash | -446.00M | -784.00M | 1476.00M | -1234.00M | -780.00M |
| Begin period cash flow | 2414.00M | 3198.00M | 1722.00M | 2956.00M | 3736.00M |
| End period cash flow | 1968.00M | 2414.00M | 3198.00M | 1722.00M | 2956.00M |
| Total cash from operating activities | 845.00M | 1019.00M | 1726.00M | 1211.00M | 2222.00M |
| Depreciation | 981.00M | 997.00M | 984.00M | 1403.00M | 890.00M |
| Other cashflows from investing activities | 3354.00M | -200.00M | 3655.00M | -252.00M | -10457.00M |
| Dividends paid | 348.00M | 590.00M | 586.00M | -573.00M | -530.00M |
| Change to inventory | -119.00M | -201.00M | -128.00M | -361.00M | -37.00M |
| Change to account receivables | -132.00M | -35.00M | -38.00M | -146.00M | -170.00M |
| Sale purchase of stock | 30.00M | 71.00M | -95.00M | -32.00M | -600.00M |
| Other cashflows from financing activities | -107.00M | -31.00M | -63.00M | 121.00M | -138.00M |
| Change to netincome | - | - | - | 3085.00M | -26.00M |
| Capital expenditures | 522.00M | 460.00M | 436.00M | 679.00M | 743.00M |
| Change receivables | - | - | - | -146.00M | -170.00M |
| Cash flows other operating | - | - | - | - | 58.00M |
| Cash and cash equivalents changes | - | - | - | -1158.00M | -733.00M |
| Change in working capital | -108.00M | -236.00M | 161.00M | -1023.00M | -161.00M |
| Stock based compensation | 117.00M | 114.00M | 115.00M | 154.00M | 146.00M |
| Other non cash items | 735.00M | 732.00M | 541.00M | 3323.00M | 198.00M |
| Free cash flow | 323.00M | 559.00M | 1290.00M | 532.00M | 1479.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BAX Baxter International Inc |
-0.50 2.13% |
23.00 | - | 11.67 | 1.07 | 1.99 | 1.73 | 26.05 |
| ISRG Intuitive Surgical Inc |
-16.75 3.73% |
432.01 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
1.51 0.74% |
205.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
2.86 2.87% |
102.66 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-0.46 0.23% |
197.88 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jose E. Almeida | Chairman, Pres & CEO | 1962 |
| Mr. James K. Saccaro | Exec. VP & CFO | 1973 |
| Mr. Giuseppe Accogli | Exec. VP & COO | 1971 |
| Mr. Andrew Frye | Pres of Patient Support Systems, Global Surgical Solutions & Enterprise Connectivity | 1965 |
| Mr. Cristiano Franzi | Sr. VP & Pres for EMEA | 1963 |
| Mr. Brian C. Stevens | Sr. VP, Chief Accounting Officer & Controller | 1975 |
| Mr. Talvis P. Love | Sr. VP & Chief Information Officer | 1968 |
| Ms. Clare Trachtman | VP of Investor Relations | NA |
| Mr. David S. Rosenbloom | Sr. VP & Gen. Counsel | NA |
| Ms. Stacey Eisen | Sr. VP of Global Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...